Kirkwood Adams, MD
Adams is an associate professor of medicine and radiology at the University of North Carolina. He specializes in heart failure, nuclear cardiology, cardiac transplantation, and general cardiology.
Hugh A. Barton, PhD
Barton currently works as a consultant for Barton Systems Pharmacology and Toxicology. His area of expertise includes translational modeling and stimulation, pharmacokinetics, and dynamics and metabolism.
Robert R. Bies, PharmD, PhD
Bies is an associate professor in the department of pharmaceutical sciences at the University of Buffalo School of Pharmacy and Pharmaceutical Sciences. He is involved in the field of pharmacometrics.
William Brock, PhD
Brock is the founder of Brock Scientific Consulting LLC which provides expert-led toxicology services to the pharmaceutical, consumer product, food, medical device, and chemical industries.
Gilbert Burckart, PharmD
Burkhart is the associate director of pediatrics in the office of clinical pharmacology at the US Food and Drug Administration.
Scott Clark, PhD
Clark, of SCSClark Networks, specializes in pharmacogenomics.
Michael Cohen-Wolkowiez, MD, PhD
Cohen-Wolkowiez is a professor of pediatrics at the Duke University School of Medicine and a member of the Duke Clinical Research Institute. He specializes in pediatric pharmacology and clinical trials.
Austin Combest, PharmD
Combest is the senior director of information and clinical science in global product development for PPD.
Ronald Fleming, PharmD
Fleming’s research area is oncology and provides expertise in the pharmaceutical industry.
John Edgar French, PhD
French is involved in research collaborations with DPET in the area of toxicology.
Giulia Ghibellini, PhD
Ghibellini is the director of clinical pharmacology at Teva Pharmaceuticals. Her research expertise is in the fields of pharmacokinetics and clinical pharmacology.
Natalia Gonzalez, MD
Gonzalez is involved in research in the area of neurology and clinical drug development.
Allison H. Harrell, PhD
Harrell is a geneticist at National Toxicology Program (NIH/NIEHS). Her area of research covers toxicology and drug-induced liver injury.
Alan Higgins, PhD
Higgins, of Baskerville Consulting, is an expert in the field of preclinical drug development.
Alison A. Motsinger-Reif, PhD
Motsinger-Reif’s research at the North Carolina State University is focused on pharmacogenetics and bioinformatics.
Kouros Owzar, PhD
Owzar is a professor of biostatistics and bioinformatics at Duke University. He specializes in cancer pharmacogenomics, drug-induced neuropathy, neutropenia and hypertension, statistical genetics, statistical methods for high-dimensional data, copulas, survival analysis, and statistical computing.
Jai Narendra Patel, PharmD
At the Carolina HealthCare System’s Levine Cancer Institute, Patel is involved in preclinical drug development research.
Kenneth Phares, PhD
Phares has extensive experience in the pharmaceutical industry, specifically in the areas of preformulation, formulation development, and bioanalytical method development.
Matthew Tyler Pletcher, PhD
Pletcher is the head of Rare Disease Discovery at Roche. His research is focused on genetics and pharmacogenomics.
Bob Powell, PharmD
Powell is a clinical pharmacologist who is interested in developing better dosing strategies in emerging markets with the goal of making drugs safer and more effective.
Virginia Schmith, PhD, FCP
Schmith has extensive research experience in clinical pharmacology and pharmacometrics.
Todd Schwartz, DrPH
Schwartz is a research associate professor of biostatistics at the UNC Gillings School of Global Public Health.
Russell Thomas, PhD
Thomas is the director for the EPA’s National Center for Computational Toxicology. His research is focused on genomic biology and bioinformatics.
Daniel Weiner, PhD
Weiner’s expertise is in the field of pharmacometrics and pharmaceutical biostatistics.
Maciej Jan Zamek-Gilszczynski, PhD
Zamek-Gilszczynski is a scientific director at GlaxoSmithKline. His research focuses on preclinical drug development.
Zhiynag Zhao, PhD
Zhao is the Chief Scientific Officer at Alliance Pharma. His area of research is pharmacokinetics and drug metabolism.